February 2018

Aurobindo Receives Approval for Sumatriptan Naproxen Sodium Tabs

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Sumatriptan and Naproxen Sodium Tablets, 85 mg/500 mg. Aurobindo’s Sumatriptan and Naproxen Sodium Tablets are an AB-rated generic equivalent to the reference listed drug Treximet®. Sumatriptan and Naproxen Sodium tablets […]

Aurobindo Receives Approval for Sumatriptan Naproxen Sodium Tabs Read More »

Aurobindo Receives FDA Approval for Niacin Extended-Release Tablets USP

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1000 mg. Aurobindo’s Niacin Extended-Release Tablets USP are an AB-rated generic equivalent to the reference listed drug NIASPAN®. Niacin Extended-Release tablets

Aurobindo Receives FDA Approval for Niacin Extended-Release Tablets USP Read More »

Aurobindo Receives FDA Approval for Niacin Extended-Release Tablets USP

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1000 mg. Aurobindo’s Niacin Extended-Release Tablets USP are an AB-rated generic equivalent to the reference listed drug NIASPAN®. Niacin Extended-Release tablets

Aurobindo Receives FDA Approval for Niacin Extended-Release Tablets USP Read More »